NICE review of Pompe therapy
Earlier this week a NICE technology appraisal advisory committee meeting took place for Avalglucosidase alfa. Part of the evidence considered was an AGSD-UK submission based on our survey of your experiences with Pompe.
Our two patient experts, nominated together with Muscular Dystrophy-UK, also gave verbal evidence and this was very much valued by the committee. We now await information on next steps and will keep you all updated.